These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38295319)

  • 21. Germline testing of
    Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
    J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
    Vanni I; Pastorino L; Andreotti V; Comandini D; Fornarini G; Grassi M; Puccini A; Tanda ET; Pastorino A; Martelli V; Mastracci L; Grillo F; Cabiddu F; Guadagno A; Coco S; Allavena E; Barbero F; Bruno W; Dalmasso B; Bellomo SE; Marchiò C; Spagnolo F; Sciallero S; Berrino E; Ghiorzo P
    J Transl Med; 2024 May; 22(1):462. PubMed ID: 38750555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disclosure of secondary findings in exome sequencing of 2480 Japanese cancer patients.
    Horiuchi Y; Matsubayashi H; Kiyozumi Y; Nishimura S; Higashigawa S; Kado N; Nagashima T; Mizuguchi M; Ohnami S; Arai M; Urakami K; Kusuhara M; Yamaguchi K
    Hum Genet; 2021 Feb; 140(2):321-331. PubMed ID: 32710294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics.
    Koster R; Schipper LJ; Giesbertz NAA; van Beek D; Mendeville M; Samsom KG; Rosenberg EH; Hogervorst FBL; Roepman P; Boelens MC; Bosch LJW; van den Berg JG; Meijer GA; Voest EE; Cuppen E; Ruijs MWG; van Wezel T; van der Kolk L; Monkhorst K
    Genet Med; 2024 Feb; 26(2):101032. PubMed ID: 38006283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Utility of Molecular Tumor Board Review for Identification of Possible Germline Pathogenic Variants on Tumor Next-Generation Sequencing Reports.
    Rives TA; Collard J; Li N; Yan D; Dietrich CS; Miller RW; Ueland FR; Pickarski J; Kolesar JM
    JCO Precis Oncol; 2024 Sep; 8():e2400301. PubMed ID: 39259913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care.
    De Silva DL; Stafford L; Skandarajah AR; Sinclair M; Devereux L; Hogg K; Kentwell M; Park A; Lal L; Zethoven M; Jayawardana MW; Chan F; Butow PN; James PA; Mann GB; Campbell IG; Lindeman GJ
    Med J Aust; 2023 May; 218(8):368-373. PubMed ID: 37005005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
    Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
    JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rate of Pathogenic Germline Variants in Patients With Lung Cancer.
    Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED
    JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study.
    Uson PLS; Riegert-Johnson D; Boardman L; Kisiel J; Mountjoy L; Patel N; Lizaola-Mayo B; Borad MJ; Ahn D; Sonbol MB; Jones J; Leighton JA; Gurudu S; Singh H; Klint M; Kunze KL; Golafshar MA; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab TS; Jewel Samadder N
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e508-e528. PubMed ID: 33857637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extended gene panel testing in lobular breast cancer.
    van Veen EM; Evans DG; Harkness EF; Byers HJ; Ellingford JM; Woodward ER; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ
    Fam Cancer; 2022 Apr; 21(2):129-136. PubMed ID: 33763779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers.
    Hao S; Zhao X; Fan Y; Liu Z; Zhang X; Li W; Yuan H; Zhang J; Zhang Y; Ma T; Tao H
    Cancer Med; 2023 Sep; 12(17):18394-18404. PubMed ID: 37610374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fanconi Anaemia, Childhood Cancer and the
    Woodward ER; Meyer S
    Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency of actionable germline pathogenic variants identified through tumor next-generation sequencing in a gynecologic cancer cohort.
    Karpel H; Manderski E; Pothuri B
    Int J Gynecol Cancer; 2023 Jul; 33(7):1044-1050. PubMed ID: 36889816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in
    Larionov A; Fewings E; Redman J; Goldgraben M; Clark G; Boice J; Concannon P; Bernstein J; Conti DV; The Wecare Study Collaborative Group ; Tischkowitz M
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Treatment-Focused Tumor Sequencing to Screen for Germline Cancer Predisposition.
    Lau TTY; May CM; Sefid Dashti ZJ; Swanson L; Starks ER; Parker JDK; Moore RA; Tucker T; Bosdet I; Young SS; Santos JL; Compton K; Heidary N; Hoang L; Schrader KA; Sun S; Kwon JS; Tinker AV; Karsan A
    J Mol Diagn; 2021 Sep; 23(9):1145-1158. PubMed ID: 34197922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of clinically relevant germline variants detected by next-generation sequencing in patients with childhood cancer: a review of the literature.
    Sylvester DE; Chen Y; Jamieson RV; Dalla-Pozza L; Byrne JA
    J Med Genet; 2018 Dec; 55(12):785-793. PubMed ID: 30287599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
    McVeigh TP; Sweeney KJ; Brennan DJ; McVeigh UM; Ward S; Strydom A; Seal S; Astbury K; Donnellan P; Higgins J; Keane M; Kerin MJ; Malone C; McGough P; McLaughlin R; O'Leary M; Rushe M; Barry MK; MacGregor G; Sugrue M; Yousif A; Al-Azawi D; Berkeley E; Boyle TJ; Connolly EM; Nolan C; Richardson E; Giffney C; Doyle SB; Broderick S; Boyd W; McVey R; Walsh T; Farrell M; Gallagher DJ; Rahman N; George AJ
    Fam Cancer; 2023 Apr; 22(2):135-149. PubMed ID: 36029389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-occurrence of germline pathogenic variants for different hereditary cancer syndromes in patients with Lynch syndrome.
    Ferrer-Avargues R; Castillejo MI; Dámaso E; Díez-Obrero V; Garrigos N; Molina T; Codoñer-Alejos A; Segura Á; Sánchez-Heras AB; Castillejo A; Soto JL
    Cancer Commun (Lond); 2021 Mar; 41(3):218-228. PubMed ID: 33630411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Germline Genetic Testing in Unselected Squamous and Non-Squamous Head and Neck Cancers.
    Brake DA; Idler BM; Kunze KL; Golafshar MA; Heald B; Young S; Klint M; Barrus K; Esplin ED; Nussbaum RL; Samadder NJ; Hinni ML; Chang BA
    Laryngoscope; 2023 Dec; 133(12):3378-3388. PubMed ID: 37132629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Universal Genetic Testing vs. Guideline-Directed Testing for Hereditary Cancer Syndromes Among Traditionally Underrepresented Patients in a Community Oncology Program.
    Jones JC; Golafshar MA; Coston TW; Rao R; Wysokinska E; Johnson E; Esplin ED; Nussbaum RL; Heald B; Klint M; Barrus K; Uson PL; Nguyen CC; Colon-Otero G; Bekaii-Saab TS; Dronca R; Kunze KL; Samadder NJ
    Cureus; 2023 Apr; 15(4):e37428. PubMed ID: 37181954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.